Humira Receives EU Approval for Ulcerative Colitis

Abbot's biologic therapy Humira has now received EU approval for the treatment of adult patients with ulcerative colitis.

Global health care company Abbott has announced that the European Commission has approved its self-injectable biologic therapy Humira (adalimumab) for the treatment of moderately to severely active ulcerative colitis.

Ulcerative colitis is a chronic inflammatory bowel disease that is characterised by diarrhoea, rectal bleeding and abdominal cramping.

Humira is approved for adult patients who have failed to achieve an adequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine.

The approval represents Humira's seventh indication in the EU, as it is already approved for the treatment of Crohn's disease, rheumatoid arthr